Policy
Maintaining America’s momentum demands that policymakers resist policies that undermine research and development incentives.
FEATURED STORIES
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are keeping many of the terms of their agreements private.
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Throughout history, many different countries have had their biopharma supply chains changed – sometimes profitably, sometimes detrimentally – by war.
The National Brain Tumor Society is investing over $1 million in the DNA damage response consortium’s start. Here’s how this consortium will help researchers.
On Monday, Arbutus and Genevant filed a lawsuit against Moderna challenging patent infringement.
The decision was intended to resolve the matter as swiftly as possible so that those who claimed to have been harmed by the product could receive expeditious compensation.
It is unknown whether tightening economic sanctions will limit Russia’s ability to ship its vaccines to areas that do not have strong manufacturing capabilities.
Studies from Guttmacher Institute found that 54% of all abortions in the United States in 2020 were done with pills instead of surgery, an increase from approximately 44% in 2019.
Not only is this the first approval for a plant-based vaccine, it’s also the first approval for GSK’s adjuvant.
After Judge Denise Cotes banned Martin Shkreli from future involvement in the industry, a second judge handed down a similar order and ordered him to pay a $1.39 million fine.
AstraZeneca and Sanofi secured accelerated authorization for respiratory syncytial virus (RSV) antibody nirsevimab from the European Medicines Agency.
Health authorities in Malawi discovered an outbreak of wild poliovirus type 1 on Thursday. The announcement comes after a case was detected in a young child in Lilongwe.